ID   LMS05
AC   CVCL_5I00
DR   cancercelllines; CVCL_5I00
DR   Cosmic; 1834892
DR   GEO; GSM482504
DR   Progenetix; CVCL_5I00
DR   Wikidata; Q54902763
RX   PubMed=22294416;
RX   PubMed=22919280;
DI   NCIt; C3158; Leiomyosarcoma
DI   ORDO; Orphanet_64720; Leiomyosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
CA   Cancer cell line
DT   Created: 14-12-15; Last updated: 05-10-23; Version: 7
//
RX   PubMed=22294416; DOI=10.1002/path.3986; PMCID=PMC3992120;
RA   Edris B., Espinosa I., Muhlenberg T., Mikels A., Lee C.-H.,
RA   Steigen S.E., Zhu S., Montgomery K.D., Lazar A.J.F., Lev D.C.,
RA   Fletcher J.A., Beck A.H., West R.B., Nusse R., van de Rijn M.;
RT   "ROR2 is a novel prognostic biomarker and a potential therapeutic
RT   target in leiomyosarcoma and gastrointestinal stromal tumour.";
RL   J. Pathol. 227:223-233(2012).
//
RX   PubMed=22919280; DOI=10.1155/2012/805614; PMCID=PMC3420093;
RA   Edris B., Fletcher J.A., West R.B., van de Rijn M., Beck A.H.;
RT   "Comparative gene expression profiling of benign and malignant lesions
RT   reveals candidate therapeutic compounds for leiomyosarcoma.";
RL   Sarcoma 2012:805614.1-805614.9(2012).
//